Drug intelligence / Profile preview

WFX-002

Development stage: Preclinical
Lead developer: Walking Fish Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

WFX-002 is an investigational cell therapy being developed by Walking Fish Therapeutics. It is based on the company's proprietary platform for engineering B cells to serve as in vivo protein factories. The therapy involves modifying B cells to produce and secrete a specific therapeutic protein. While the exact protein and the target disease indication for WFX-002 remain undisclosed, the platform is designed to provide long-term, stable expression of therapeutic proteins for various conditions, potentially including rare diseases or oncology. The candidate is currently in the preclinical stage of development.

Beyond the preview

Go deeper on WFX-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WFX-002.

Explore the full profile